Neumora Therapeutics IPO Presentation Deck
September 2023, 32 slides
  1. Neumora Therapeutics
  2. Related Decks
  3. IPO Presentation Decks
pioneering a new era of innovation for brain disease | Neumora Therapeutics
important disclosures | Neumora Therapeutics
offering summary | Neumora Therapeutics
our mission | Neumora Therapeutics
focused on building the leading global brain health company built at scale leading pipeline near term catalysts | Neumora Therapeutics
led by experienced company builders and leading drug developers surveyor | Neumora Therapeutics
advancing our pipeline | Neumora Therapeutics
kor antagonism has potential for broad neuropsychiatric impact potential to be first novel mechanism approved in in decades | Neumora Therapeutics
| Neumora Therapeutics
established proof of concept for treatment of depression and anhedonia in patients with moderate to severe | Neumora Therapeutics
demonstrated efficacy across broad range of treatment outcome measures in moderate to severe population | Neumora Therapeutics
well tolerated with lower incidence rate compared to placebo | Neumora Therapeutics
pivotal studies designed to evaluate potential benefits of in | Neumora Therapeutics
differentiated profile relative to approved agents drives physician preference | Neumora Therapeutics
market in provides potential large blockbuster opportunity for differentiated product with novel mechanism of action upside drivers agent drives | Neumora Therapeutics
potential for broad applicability of beyond includes bipolar depression | Neumora Therapeutics
antagonist broad potential across neuropsychiatric disorders i | Neumora Therapeutics
demonstrates relevant pharmacodynamics with the potential to address anxiety disorders | Neumora Therapeutics
potentially differentiated pam for schizophrenia | Neumora Therapeutics
profile of is comparable to other programs | Neumora Therapeutics
novel approach for the treatment of schizophrenia | Neumora Therapeutics
for amyotrophic lateral sclerosis | Neumora Therapeutics
precision strategy for in amyotrophic lateral sclerosis als incorporates drug specific properties to define potential best responders | Neumora Therapeutics
for disease | Neumora Therapeutics
for disease | Neumora Therapeutics
precision medicine approach can be leveraged to maximize the value of our programs | Neumora Therapeutics
building a company with the scale and scope to address the brain disease crisis for patients | Neumora Therapeutics
is poised to become the leader in brain health with multiple catalysts expected through to drive value | Neumora Therapeutics
appendix | Neumora Therapeutics
| Neumora Therapeutics
phase efficacy population patient demographics and characteristics similar across treatment groups | Neumora Therapeutics
demonstrated statistically significant and clinically meaningful improvements in depression and anhedonia despite inclusion of mild patients | Neumora Therapeutics
See More
Neumora Therapeutics
IPO Presentation Decks
Drug Manufacturers—Specialty & Generic Decks
Healthcare Decks
Explore Topics
Anxiety
Related decks
ATAI
Investor Presentation
March 2023
MindMed
Investor Day
June 2023
ATAI
Investor Presentation
October 2022
ATAI
Investor Conference
May 2023
ATAI
Investor Presentation
June 2020
MindMed
Investor Presentation
April 2021
ATAI
Investor Presentation
April 2023
ATAI
Investor Presentation
February 2023
ATAI
Investor Presentation
March 2023
MindMed
Investor Day
June 2023
ATAI
Investor Presentation
October 2022
ATAI
Investor Conference
May 2023
ATAI
Investor Presentation
June 2020
MindMed
Investor Presentation
April 2021
ATAI
Investor Presentation
April 2023
ATAI
Investor Presentation
February 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io